Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

A 60-year-old man regains mobility after advanced treatment. AGMC and GB Pant Hospital in Tripura mark a milestone in ...

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Key Points GAAP EPS loss was $(0.88) for Q2 2025 GAAP revenue was $0.2 million for Q2 2025 Research and development expenses increased by 45.3%, while general and administrative expenses rose by 48.3% ...

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis (MG). | Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis.

After years of unexplained pain in her joints, nerves, and stomach, this writer finally found some relief—and a new community ...

武田制药的HyQvia被批准用于原发性免疫缺陷十年后，FDA批准了其第二个适应症。现在，该疗法可为慢性炎症性脱髓鞘性多发性神经病（CIDP）患者提供了一种多样化的治疗选择，允许患者自行给药或在各种医疗机构中接受治疗。